• Research indicates CRC-446 as a pharma signpost for colorectal cancer
    Pharma professionals are told of a link between decreased CRC-446 and increased colorectal cancer risk


Research indicates CRC-446 as a pharma signpost for colorectal cancer

Dec 01 2010

A study of individuals aged from 11 to 99 years old and located in North America and Japan indicates new ways for pharma professionals to predict colorectal cancer risk.

Writing in BMC Gastroenterology, a team of scientists explain how they used tandem mass spectrometry to detect serum levels of the 28 carbon-containing hydroxy polyunsaturated ultra long-chain fatty acid C28H46O4 (CRC-446).

They found an inverse correlation between levels of CRC-446 and increased risk of developing colorectal cancer.

However, the serum levels seen in test subjects were independent of any pharma intervention designed to combat previous colorectal tumours.

As a result, the scientists recommend using CRC-446 serum levels as an alternative to colonoscopies to predict cancer risk, with the potential to reduce the need for the invasive procedure by 80 per cent.

The periodical provides open access to findings and discussions of all elements relating to diagnosis, management and prevention of gastrointestinal disease.

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Lab Asia 2023

Oct 10 2023 Hybrid event

MicroTAS 2023

Oct 15 2023 Katowice, Poland

ISPPP 2023

Nov 05 2023 Vienna, Austria

SETAC North America

Nov 12 2023 Louisville, KY, USA

Eastern Analytical Symposium

Nov 13 2023 Plainsboro, NJ, USA

View all events